Apr 21, 2021 8:30am EDT Veru Announces Presentation of Phase 2 Study of Enobosarm -- a Selective Androgen Receptor Targeting Agent in Metastatic AR+ER+HER2- Breast Cancer at 2021 ESMO Breast Cancer Congress
Mar 02, 2021 8:30am EST Veru to Participate in Fireside Chat at the H.C. Wainwright Global Life Sciences Conference
Mar 01, 2021 8:30am EST Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)
Feb 10, 2021 6:30am EST Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Quarter
Feb 08, 2021 7:30am EST Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
